461 related articles for article (PubMed ID: 31351173)
1. Dynamic behaviors of α-synuclein and tau in the cellular context: New mechanistic insights and therapeutic opportunities in neurodegeneration.
Yeboah F; Kim TE; Bill A; Dettmer U
Neurobiol Dis; 2019 Dec; 132():104543. PubMed ID: 31351173
[TBL] [Abstract][Full Text] [Related]
2. The interaction of α-synuclein and Tau: A molecular conspiracy in neurodegeneration?
Yan X; Uronen RL; Huttunen HJ
Semin Cell Dev Biol; 2020 Mar; 99():55-64. PubMed ID: 29738880
[TBL] [Abstract][Full Text] [Related]
3. Tau is required for progressive synaptic and memory deficits in a transgenic mouse model of α-synucleinopathy.
Singh B; Covelo A; Martell-Martínez H; Nanclares C; Sherman MA; Okematti E; Meints J; Teravskis PJ; Gallardo C; Savonenko AV; Benneyworth MA; Lesné SE; Liao D; Araque A; Lee MK
Acta Neuropathol; 2019 Oct; 138(4):551-574. PubMed ID: 31168644
[TBL] [Abstract][Full Text] [Related]
4. Distinct α-Synuclein strains and implications for heterogeneity among α-Synucleinopathies.
Peng C; Gathagan RJ; Lee VM
Neurobiol Dis; 2018 Jan; 109(Pt B):209-218. PubMed ID: 28751258
[TBL] [Abstract][Full Text] [Related]
5. Vesicle trafficking and lipid metabolism in synucleinopathy.
Fanning S; Selkoe D; Dettmer U
Acta Neuropathol; 2021 Apr; 141(4):491-510. PubMed ID: 32607605
[TBL] [Abstract][Full Text] [Related]
6. [Prion-like Propagation of Pathological α-Synuclein in Vivo].
Masuda-Suzukake M; Hasegawa M
Yakugaku Zasshi; 2019; 139(7):1007-1013. PubMed ID: 31257247
[TBL] [Abstract][Full Text] [Related]
7. Phosphorylated Smad 2/3 colocalizes with phospho-tau inclusions in Pick disease, progressive supranuclear palsy, and corticobasal degeneration but not with alpha-synuclein inclusions in multiple system atrophy or dementia with Lewy bodies.
Chalmers KA; Love S
J Neuropathol Exp Neurol; 2007 Nov; 66(11):1019-26. PubMed ID: 17984683
[TBL] [Abstract][Full Text] [Related]
8. More than just two peas in a pod: common amyloidogenic properties of tau and alpha-synuclein in neurodegenerative diseases.
Lee VM; Giasson BI; Trojanowski JQ
Trends Neurosci; 2004 Mar; 27(3):129-34. PubMed ID: 15036877
[TBL] [Abstract][Full Text] [Related]
9. Like prions: the propagation of aggregated tau and α-synuclein in neurodegeneration.
Goedert M; Masuda-Suzukake M; Falcon B
Brain; 2017 Feb; 140(2):266-278. PubMed ID: 27658420
[TBL] [Abstract][Full Text] [Related]
10. Filamentous nerve cell inclusions in neurodegenerative diseases: tauopathies and alpha-synucleinopathies.
Goedert M
Philos Trans R Soc Lond B Biol Sci; 1999 Jun; 354(1386):1101-18. PubMed ID: 10434313
[TBL] [Abstract][Full Text] [Related]
11. Loss of tau expression attenuates neurodegeneration associated with α-synucleinopathy.
Vermilyea SC; Christensen A; Meints J; Singh B; Martell-Martínez H; Karim MR; Lee MK
Transl Neurodegener; 2022 Jul; 11(1):34. PubMed ID: 35773715
[TBL] [Abstract][Full Text] [Related]
12. The emerging role of α-synuclein truncation in aggregation and disease.
Sorrentino ZA; Giasson BI
J Biol Chem; 2020 Jul; 295(30):10224-10244. PubMed ID: 32424039
[TBL] [Abstract][Full Text] [Related]
13. alpha-Synuclein and its disease-related mutants interact differentially with the microtubule protein tau and associate with the actin cytoskeleton.
Esposito A; Dohm CP; Kermer P; Bähr M; Wouters FS
Neurobiol Dis; 2007 Jun; 26(3):521-31. PubMed ID: 17408955
[TBL] [Abstract][Full Text] [Related]
14. Interactions Between α-Synuclein and Tau Protein: Implications to Neurodegenerative Disorders.
Li X; James S; Lei P
J Mol Neurosci; 2016 Nov; 60(3):298-304. PubMed ID: 27629562
[TBL] [Abstract][Full Text] [Related]
15. Human cyclophilin 40 unravels neurotoxic amyloids.
Baker JD; Shelton LB; Zheng D; Favretto F; Nordhues BA; Darling A; Sullivan LE; Sun Z; Solanki PK; Martin MD; Suntharalingam A; Sabbagh JJ; Becker S; Mandelkow E; Uversky VN; Zweckstetter M; Dickey CA; Koren J; Blair LJ
PLoS Biol; 2017 Jun; 15(6):e2001336. PubMed ID: 28654636
[TBL] [Abstract][Full Text] [Related]
16. Protein aggregation and neurodegeneration in prototypical neurodegenerative diseases: Examples of amyloidopathies, tauopathies and synucleinopathies.
Bourdenx M; Koulakiotis NS; Sanoudou D; Bezard E; Dehay B; Tsarbopoulos A
Prog Neurobiol; 2017 Aug; 155():171-193. PubMed ID: 26209472
[TBL] [Abstract][Full Text] [Related]
17. Deposition of Phosphorylated α-Synuclein in the rTg4510 Mouse Model of Tauopathy.
Takaichi Y; Ano Y; Chambers JK; Uchida K; Takashima A; Nakayama H
J Neuropathol Exp Neurol; 2018 Oct; 77(10):920-928. PubMed ID: 30107539
[TBL] [Abstract][Full Text] [Related]
18. Patterns of Tau and α-Synuclein Pathology in the Visual System.
Rahimi J; Milenkovic I; Kovacs GG
J Parkinsons Dis; 2015; 5(2):333-40. PubMed ID: 25737267
[TBL] [Abstract][Full Text] [Related]
19. Alpha-synuclein and tau: teammates in neurodegeneration?
Moussaud S; Jones DR; Moussaud-Lamodière EL; Delenclos M; Ross OA; McLean PJ
Mol Neurodegener; 2014 Oct; 9():43. PubMed ID: 25352339
[TBL] [Abstract][Full Text] [Related]
20. Unveiling transient protein-protein interactions that modulate inhibition of alpha-synuclein aggregation by beta-synuclein, a pre-synaptic protein that co-localizes with alpha-synuclein.
Janowska MK; Wu KP; Baum J
Sci Rep; 2015 Oct; 5():15164. PubMed ID: 26477939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
